Barclays Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $32.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target cut by Barclays from $43.00 to $32.00 in a research note published on Friday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

RARE has been the subject of a number of other reports. Canaccord Genuity Group reduced their price objective on shares of Ultragenyx Pharmaceutical from $83.00 to $37.00 and set a “buy” rating for the company in a research report on Thursday. William Blair lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Thursday. Wedbush dropped their price objective on shares of Ultragenyx Pharmaceutical from $30.00 to $23.00 and set a “neutral” rating on the stock in a research report on Thursday. Cantor Fitzgerald cut their target price on shares of Ultragenyx Pharmaceutical from $103.00 to $33.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, Citigroup reduced their target price on shares of Ultragenyx Pharmaceutical from $58.00 to $28.00 and set a “buy” rating for the company in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $36.63.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $15.30 on Friday. Ultragenyx Pharmaceutical has a 52 week low of $13.81 and a 52 week high of $39.89. The stock has a market capitalization of $1.51 billion, a P/E ratio of -2.62 and a beta of 0.31. The stock has a 50-day simple moving average of $27.76 and a 200 day simple moving average of $25.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The firm had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. During the same quarter in the prior year, the company earned ($1.17) earnings per share. The business’s revenue for the quarter was up 28.5% compared to the same quarter last year. Research analysts forecast that Ultragenyx Pharmaceutical will post -3.98 earnings per share for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Karah Parschauer sold 1,899 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the transaction, the executive vice president owned 94,462 shares in the company, valued at $2,325,654.44. This trade represents a 1.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Corsee Sanders sold 2,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the sale, the director directly owned 21,095 shares of the company’s stock, valued at $528,429.75. This represents a 8.66% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 5.20% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Corient Private Wealth LP boosted its holdings in Ultragenyx Pharmaceutical by 7.3% in the 2nd quarter. Corient Private Wealth LP now owns 146,493 shares of the biopharmaceutical company’s stock valued at $4,891,000 after purchasing an additional 9,949 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $1,036,000. California State Teachers Retirement System increased its holdings in shares of Ultragenyx Pharmaceutical by 3,137.6% during the second quarter. California State Teachers Retirement System now owns 3,388,117 shares of the biopharmaceutical company’s stock worth $113,129,000 after purchasing an additional 3,283,467 shares during the period. denkapparat Operations GmbH bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $230,000. Finally, Nykredit A S acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $154,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Several analysts still see substantial potential upside after the selloff. Barclays maintained an “overweight” rating with a $32 price target, while Jefferies, Citigroup, TD Cowen, Canaccord Genuity, Cantor Fitzgerald and HC Wainwright retained bullish ratings despite sharply reducing their targets.
• Positive Sentiment: Ultragenyx is evaluating “significant” cost reductions following the trial failure, which could help preserve cash and improve the company’s financial outlook. Investors are also focusing on its existing commercial rare-disease portfolio. Ultragenyx to weigh significant cost cuts as Angelman drug fails key study
• Positive Sentiment: Unusually heavy call-option activity and speculation that Ultragenyx could become an acquisition target provide potential—but highly speculative—support for the stock. Ultragenyx potential M&A target
• Neutral Sentiment: Analyst views are increasingly divided. Goldman Sachs lowered its target to $19 and moved to “neutral,” while Barclays remains “overweight” at $32. Jefferies and Citi kept “buy” ratings but reduced targets to $28. The wide range reflects uncertainty over Ultragenyx’s post-trial growth prospects.
• Negative Sentiment: RBC downgraded the company to “hold,” while Bank of America, JPMorgan, Wells Fargo, Baird, Evercore, William Blair and others also reduced ratings or targets. Baird and Evercore now see only limited upside, signaling diminished confidence in the pipeline.
• Negative Sentiment: The Angelman syndrome failure creates greater dependence on Ultragenyx’s existing products and other pipeline programs. The company is weighing the future of the program, adding uncertainty around research spending, revenue growth and long-term valuation. Ultragenyx Angelman syndrome trial failure

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.